about
Nonalcoholic fatty liver disease, portal vein thrombosis and coagulation: more questions than answers?Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock?Reply to "HbA1c levels as a parameter of glycemic control in patients with liver cirrhosis".Coagulopathy Before and After Liver Transplantation: From the Hepatic to the Systemic Circulatory Systems.Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C.Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis.Vasopressin use in critically ill cirrhosis patients with catecholamine-resistant septic shock: The CVICU cohort.Drug Hepatotoxicity: Environmental Factors.Liver transplant recipients with portal vein thrombosis receiving an organ from a high-risk donor are at an increased risk for graft loss due to hepatic artery thrombosis.Autoimmune-like drug-induced liver injury: a review and update for the clinician.Pre-transplant portal vein thrombosis is an independent risk factor for graft loss due to hepatic artery thrombosis in liver transplant recipientsCurrent and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.Chronic liver injury induced by drugs: a systematic review.Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis.Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series.Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis.Immunosuppressed solid organ transplant recipient.The safety of same-day endoscopy and percutaneous liver biopsy.Drug-induced liver injury: a summary of recent advances.Hepatotoxicity of antibiotics: a review and update for the clinician.Decreased Portal Vein Velocity is Predictive of the Development of Portal Vein Thrombosis: a Matched Case-Control Study.Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs?Portal vein thrombosis after hepatitis C eradication with direct acting antiviral therapy.Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-α inhibitor therapy.Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir.Liquid sucrose bingeing in rats depends on the access schedule, concentration and delivery system.Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis.Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseasesPhysical deconditioning is the common denominator in both obese and overweight subjects with nonalcoholic steatohepatitisTreatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical TrialVenous thromboembolism in patients with liver diseases: commentCoronary artery disease in decompensated patients undergoing liver transplantation evaluationLiver transplant candidates have impaired quality of life across health domains as assessed by computerized testingHypercoagulability in End-stage Liver Disease: Review of Epidemiology, Etiology, and ManagementManagement of Non-tumoral Portal Vein Thrombosis in Patients with CirrhosisClinical Cirrhosis Dilemmas: Survey of Practice from the 7th International Coagulation in Liver Disease ConferenceConcise Commentary: The Clot Thickens-Why Pylephlebitis Is One of the Most Feared Complications of Intra-abdominal SepsisPerioperative thrombotic complications associated with pediatric liver transplantation: a UNOS database evaluationHyponatremia Is Protective Against the Development of Portal Vein Thrombosis in Patients Undergoing Liver Transplant
P50
Q30252457-28910B41-D2C0-4077-A19E-8ADDD747C5B8Q30252463-A5A00D00-73A9-47BF-9E1E-E10CF8B190DCQ30252587-A72154B5-EF03-4A15-AC6D-2F8780152F38Q30252750-7AB06017-491F-4211-B092-23C3B0764813Q30268489-BD8AB954-CC10-44B6-8F3A-DA6C39F18775Q30274723-0E551D9A-62E9-4D3E-A685-5D214B665AD7Q30274871-CACC60C3-7721-43B8-9D9A-57D44FCFFC31Q30275418-96EA653A-4B80-4981-B940-858510FEAA20Q30275773-8572A657-F742-483C-A8A6-12A1CFE734A6Q30276377-4DA70ECA-5CA2-4375-8B3D-B1F5FBDF5156Q30277088-914BA3FF-8681-499C-93B9-CFE28279C514Q30277969-C13AC219-B5C5-431A-9918-91A4F476F07BQ30278737-CB0749C0-2090-4D70-AC11-4666AED57349Q30300233-F9D8BB10-39CA-4172-AF06-D64AC023F45CQ30300424-D454A158-9DE5-40F1-8F99-C4D05EB88610Q30301355-874C0E48-7194-4568-ABA5-6EFE3B827C2BQ30457237-20E8AC21-76DA-49CB-977C-27BD8A3A1529Q37790637-84DA0E70-41A0-4E0B-9759-4099DDA5AB76Q37867695-6F95C99C-895A-430F-A605-291418C55104Q38149900-A1FEE252-0472-4B7C-8971-C9CED321843AQ38668946-57E420E3-9A9F-496A-8D42-DFD85B24FA6EQ42993023-106B4C4B-5CBC-4F72-A774-45B4B6BB2E6EQ45064843-4344E83C-AC31-4D32-A8D9-5A76DF776B4EQ45361701-950EF686-B0DC-4EFC-B8DA-057B3279B8B9Q45376062-BAC30B27-862F-4CDF-84D9-16395868B8B3Q50282535-13BEF149-2EED-42CA-94EA-0D51684D4B6BQ53566587-9B2E050B-3EE4-4140-949C-6067569D45B8Q55342502-80401B19-DC85-4C6F-8395-70DFAA461F4CQ56333985-09D18F3B-F781-47CC-B339-7644C6078E78Q56334550-CE059B2A-74A1-441A-8D5F-D545BC2838C8Q56381036-9B28A03D-6E2A-40EC-B75D-AD529E456CF2Q58546400-2D77E4B2-E2B8-438D-9BD2-DF4061456AFCQ88231445-83124E00-B86C-41C5-A7BA-E1B7ECDA102BQ90314994-9933ABD9-299D-44E8-8C93-3D294BFDBBD6Q90388064-B8EFA202-8AD1-4A25-B471-92C038F3CD75Q90601597-B127AA86-FF6C-4A08-9BDB-5073A220DC29Q90813888-B478F6C0-87B7-42D5-9D72-EF9BA867A2A6Q90859458-BAF9BC57-1288-4782-A53A-CAAED1DB9A6DQ91856796-76EAA485-8212-41F8-98F0-A9193EE44825Q92531766-7B5C4293-3087-4675-BADA-1D733C909C3A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jonathan G Stine
@ast
Jonathan G Stine
@en
Jonathan G Stine
@es
Jonathan G Stine
@nl
Jonathan G Stine
@sl
type
label
Jonathan G Stine
@ast
Jonathan G Stine
@en
Jonathan G Stine
@es
Jonathan G Stine
@nl
Jonathan G Stine
@sl
prefLabel
Jonathan G Stine
@ast
Jonathan G Stine
@en
Jonathan G Stine
@es
Jonathan G Stine
@nl
Jonathan G Stine
@sl
P106
P21
P31
P496
0000-0002-3352-6928